WTx-901

WTx-901 is a bispecific antibody-drug conjugate-like molecule (BAM) currently in the lead optimization phase of development by Window Therapeutics. It is built upon the company's proprietary BAM platform, which is designed to create next-generation targeted therapies that combine the dual-targeting capabilities of bispecific antibodies with the potent cell-killing effects of drug conjugates. Although the specific molecular targets and therapeutic indications for WTx-901 have not been publicly disclosed, the BAM technology is typically applied to oncology to improve selectivity and overcome resistance mechanisms by targeting two distinct antigens simultaneously.